Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2016 - 2025)

Arrowhead Pharmaceuticals' Non Operating Income history spans 16 years, with the latest figure at -$12.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 3776.83% year-over-year to -$12.5 million; the TTM value through Dec 2025 reached -$33.6 million, down 4941.08%, while the annual FY2025 figure was -$46.8 million, 2578.09% down from the prior year.
  • Non Operating Income reached -$12.5 million in Q4 2025 per ARWR's latest filing, down from -$8.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.8 million in Q1 2022 to a low of -$13.5 million in Q2 2025.
  • Average Non Operating Income over 5 years is -$1.8 million, with a median of -$433000.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: soared 2657.27% in 2022, then tumbled 3776.83% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$707000.0 in 2021, then surged by 148.09% to $340000.0 in 2022, then crashed by 730.59% to -$2.1 million in 2023, then soared by 115.9% to $341000.0 in 2024, then crashed by 3776.83% to -$12.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Non Operating Income are -$12.5 million (Q4 2025), -$8.0 million (Q3 2025), and -$13.5 million (Q2 2025).